Cerebrospinal Fluid Proteomic Changes after Nusinersen in Patients with Spinal Muscular Atrophy
Journal of Clinical Medicine · 23.10.2023 · 12 (20) · 6696
DOI: 10.3390/jcm12206696 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 23.10.2023. Verfasst von Marie Beaudin und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology and Neurological Sciences, Stanford School of Medicine, Stanford, CA 94304, USA. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Biogen (United States), Spinal Muscular Atrophy Foundation, SMA Foundation.
Abstract (Originalsprache)
Disease-modifying treatments have transformed the natural history of spinal muscular atrophy (SMA), but the cellular pathways altered by SMN restoration remain undefined and biomarkers cannot yet precisely predict treatment response. We performed an exploratory cerebrospinal fluid (CSF) proteomic study in a diverse sample of SMA patients treated with nusinersen to elucidate therapeutic pathways and identify predictors of motor improvement. Proteomic analyses were performed on CSF samples collected before treatment (T0) and at 6 months (T6) using an Olink panel to quantify 1113 peptides. A supervised machine learning approach was used to identify proteins that discriminated patients who improved functionally from those who did not after 2 years of treatment. A total of 49 SMA patients were included (10 type 1, 18 type 2, and 21 type 3), ranging in age from 3 months to 65 years. Most proteins showed a decrease in CSF concentration at T6. The machine learning algorithm identified ARSB, ENTPD2, NEFL, and IFI30 as the proteins most predictive of improvement. The machine learning model was able to predict motor improvement at 2 years with 79.6% accuracy. The results highlight the potential application of CSF biomarkers to predict motor improvement following SMA treatment. Validation in larger datasets is needed.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neurology and Neurological Sciences, Stanford School of Medicine, Stanford, CA 94304, USA.
- Department of Neurology, Stanford Health Care, Stanford, CA 94304, USA.
ORCID-Profile: Marie Beaudin, Katharine A Hagerman, Sally Dunaway Young, Dana M Parker
Förderung
- Biogen (United States)
- Spinal Muscular Atrophy Foundation
- SMA Foundation
Zitieren
APA
Beaudin, M., Kamali, T., Tang, W., Hagerman, K. A., Dunaway Young, S., Ghiglieri, L., Parker, D. M., Lehallier, B., Tesi-Rocha, C., Sampson, J. B., Duong, T., & Day, J. W. (2023). Cerebrospinal Fluid Proteomic Changes after Nusinersen in Patients with Spinal Muscular Atrophy. Journal of Clinical Medicine, 12(20), 6696. https://doi.org/10.3390/jcm12206696
Vancouver
Beaudin M, Kamali T, Tang W, Hagerman KA, Dunaway Young S, Ghiglieri L, et al. Cerebrospinal Fluid Proteomic Changes after Nusinersen in Patients with Spinal Muscular Atrophy. Journal of Clinical Medicine. 2023;12(20):6696. doi:10.3390/jcm12206696
BibTeX
@article{Beaudin2023,
author = {Beaudin, Marie and Kamali, Tahereh and Tang, Whitney and Hagerman, Katharine A and Dunaway Young, Sally and Ghiglieri, Lisa and Parker, Dana M and Lehallier, Benoit and Tesi-Rocha, Carolina and Sampson, Jacinda B and Duong, Tina and Day, John W},
title = {Cerebrospinal Fluid Proteomic Changes after Nusinersen in Patients with Spinal Muscular Atrophy},
journal = {Journal of Clinical Medicine},
year = {2023},
volume = {12},
number = {20},
pages = {6696},
doi = {10.3390/jcm12206696}
}
EUVIMED